Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!

Retinitis Pigmentosa

View All

The Hidden World of Vision: Exploring the Top 5 Rare Eye Diseases

Rare diseases affect a larger population than cancer and AIDS combined, with over 7,000 distinct conditions impacting more than 300 million globally. Approximately 1 in 10 individuals are affected by a rare disease, and it often requires several years to receive an accurate diagnosis, averaging around 4.8 years. Ap...

Find More

Cell and Gene Therapies in Rare Disorders: From Rarity to Recovery

The cell and gene therapy market has seen a revolutionary transition in recent years, with advancements in scientific research and novel methods of treatment driving a rise in development activities. This has resulted in an increase in the number of cell and gene therapy choices available to patients suffering from...

Find More

Pharma News and updates for HUTCHMED, Cytokinetics, Astellas, Seagen, Nanoscope Therapeutics, Cabaletta Bio, Decibel Therapeutics
HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...

Find More

Pharma News Updates for Merck, Sanofi, GSK, Hinova, Endogena, Amylyx
Merck’s Keytruda Wins Another FDA Approval; Sanofi Pauses Trial of Myasthenia Gravis Drug, tolebrutinib; FDA Approves GlaxoSmithKline’s Jesduvroq; FDA IND Application Clearance for Hinova’s HP518; FDA Fast Track Designation to Endogena’s EA-2353; Amylyx Updates on Global Phase 3 PHOENIX Trial

Merck Wins Another FDA Approval for Blockbuster Keytruda Merck & Co arrived just two months after GSK celebrated a positive phase III result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer. Keytruda (pembrolizumab) from Merck improved progression-free survival (PFS) vers...

Find More

Pharma News for Actinium, Santhera, Gilead, Seres, BMS, Boehringer
Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...

Find More

Pharma News Merck, AstraZeneca, and GSK
Merck’s Sotatercept Trial Result; PARP Rivals Closing in on AstraZeneca and Merck’s Lynparza; FDA Clears GSK’s Boostrix for Pertussis; Fast Track Designation to Nanoscope Therapeutics’s MCO-010; FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab; Solid Biosciences to Acquire AavantiBio

Merck’s Sotatercept Clears Phase III Trial Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin re...

Find More

Retinitis pigmentosa
What is driving Retinitis pigmentosa market forward?

DelveInsight estimates an increase in Retinitis Pigmentosa Market Size during the study period 2017–2030, from USD 237.27 million, as reported in 2017 in the 7MM. The increase in the Retinitis pigmentosa market size, as estimated by DelveInsight, is a direct consequence of the expected launch of potential therap...

Find More

Retinitis Pigmentosa
Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence

DelveInsight’s Retinitis Pigmentosa Epidemiology forecast analysis revealed that the prevalent population of the disease is expected to increase during the study period 2017-30. Retinitis Pigmentosa Defects and Diagnosis A group of inherited genetic retinal diseases – Retinitis pigmentosa – leads to progressi...

Find More


UK based company conducting clinical trials on World's First Universal Flu Vaccine UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu probl...

Find More

Retinal Degeneration
Retinal Degeneration : The Current Pipeline Scenario

Retinal Degeneration is the deterioration of the retina caused by the progressive and eventual death of the retinal cells. It is the damage to photoreceptor cells of the retina which malfunctions and distorts the received image. This is often a progressive disease in which the patient will suffer a continuous declin...

Find More